JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

JNJ

227.38

+0.01%↑

ISRG

503.63

-0.84%↓

ABT

109.23

+3.01%↑

RDY

13.4

+1.06%↑

NEOG

10.21

+0.1%↑

Начало・Списък с акции・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

20.34 -1.41

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

20.19

Максимум

20.49

Ключови измерители
By Trading Economics
Приходи	11M -61M
Продажби	7.9M 46M
Марж на печалбата	-132.36
Служители	270
EBITDA	6.3M -58M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+92.57% upside

Дивиденти
By Dow Jones
Следващи печалби	2.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	731M 1.9B
Предишно отваряне	21.75
Предишно затваряне	20.34

Настроения в новините

By Acuity

63%

37%

300 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

9.91 / 14.15 Подкрепа & съпротива

Syndax Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.02.2026 г., 23:59 ч. UTC

Пазарно говорене

Oil Prices Fall Amid Signs of U.S.-Iran Negotiations -- Market Talk

1.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

1.02.2026 г., 23:44 ч. UTC

Пазарно говорене

Gold Falls as Markets Further Price in Warsh-Led Fed -- Market Talk

1.02.2026 г., 12:47 ч. UTC

Придобивния, сливания и поглъщания

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion -- Update

1.02.2026 г., 03:02 ч. UTC

Придобивния, сливания и поглъщания

KKR-Led Group Set to Buy Singapore Data-Center Firm Valued at Over $10 Billion

1.02.2026 г., 03:01 ч. UTC

Придобивния, сливания и поглъщания

KKR Consortium Currently Owns Near 20% Stake in STT GDC

1.02.2026 г., 03:01 ч. UTC

Придобивния, сливания и поглъщания

KKR Consortium Acquiring Remaining Stake in STT GDC With Singtel, Sources Say

31.01.2026 г., 18:48 ч. UTC

Придобивния, сливания и поглъщания

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- Update

31.01.2026 г., 16:40 ч. UTC

Печалби

'All Boats Are Rising' in Data and Memory, Says Western Digital's CFO. Just Look at the Stocks. -- Barrons.com

31.01.2026 г., 09:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Negotiations Over $100B OpenAI, Nvidia Deal Stall -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia, OpenAI in Talks to Revise Nature of Broader Partnership, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia CEO Jensen Huang Has Privately Told Colleagues That Deal Is Non-Binding, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia's Huang Has Privately Criticized OpenAI's Business Strategy, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

OpenAI, Nvidia Deal Talks Stalled in Recent Months, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia's Huang Expressed Concerns Over Competition OpenAI Faces From Anthropic, Google, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Nvidia Weighing Equity Investment of Tens of Billions of Dollars Into OpenAI, Sources Say -- WSJ

30.01.2026 г., 23:47 ч. UTC

Придобивния, сливания и поглъщания

Negotiations Over $100B OpenAI, Nvidia Deal Stall, Sources Say -- WSJ

30.01.2026 г., 23:41 ч. UTC

Пазарно говорене

Deckers Outdoor Seen as Undervalued -- Market Talk

30.01.2026 г., 23:12 ч. UTC

Придобивния, сливания и поглъщания

Supreme Court of British Columbia Approves Fortescue Purchase of Alta Copper

30.01.2026 г., 22:20 ч. UTC

Печалби

Verizon Posts Strong Subscriber Gains Under New CEO -- WSJ

30.01.2026 г., 22:10 ч. UTC

Пазарно говорене

Disney CEO's Exit Plan Marks Abrupt End to Messy Succession -- Market Talk

30.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

30.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

30.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

30.01.2026 г., 21:42 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30.01.2026 г., 21:36 ч. UTC

Печалби

GE Aerospace and GE Vernova Issue Their Annual Reports. They Contain Messages for Investors. -- Barrons.com

30.01.2026 г., 21:33 ч. UTC

Печалби

Tesla Stock Rebounds From Earnings Dip. SpaceX Is Helping. -- Barrons.com

30.01.2026 г., 20:42 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Verizon, SoFi, Sandisk, Western Digital, Unity Software, Exxon, and More -- Barrons.com

30.01.2026 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Why a Ruling Over CK Hutchison's Panama Canal Ports Matters -- and What's Next -- WSJ

Сравнение с други в отрасъла

Ценова промяна

Syndax Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

92.57% нагоре

12-месечна прогноза

Среден 39.11 USD 92.57%

Висок 56 USD

Нисък 27 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Syndax Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Syndax Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

9.91 / 14.15Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Настроение

By Acuity

300 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.